DanCann Pharma A/S: Submits applications for FLS03 and FLS04 to expand portfolio
COPENHAGEN, Denmark, 12 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, has formally submitted applications for two additional medicines to enrich the existing portfolio with the Danish Medicines Agency under the Danish Pilot Programme for medicinal cannabis.Submission of two new applications: · FLS04, CBD-granulate · FLS05, THC-flos The applications encompass two new medicines, poised to complement the current trio of approved products (Bedrocan®, Bedica®, and Bediol®). These include a THC-dominant